What is the revenue and EPS growth rate for Karyopharm year over year?

What is Karyopharm's gross profit margin?

What were the key takeaways from Karyopharm’s earnings call?

What were the key takeaways from Karyopharm's earnings call?

What guidance did Karyopharm's management provide for the next earnings period?

What is Karyopharm's latest dividend and current dividend yield?

What does Karyopharm do and what are its main business segments?

What is the market's earnings forecast for Karyopharm next quarter?

- **Phase III SENTRY Trial Milestone**: Enrollment complete, targeting March 2026 readout with 79% SVR35 vs. 35% for ruxolitinib alone.
- **Revenue Growth**: Q3 2025 total revenue $44M (+13% YoY), XPOVIO net product revenue $32M (+8.5% YoY).
- **$1B Myelofibrosis Opportunity**: 75% physician intent for combination therapy in 4,000 new U.S. patients/year.
- **Financial Flexibility**: $100M refinancing extends cash runway to Q2 2026, with no additional sales force needed.
- **Safety Profile**: Combination therapy shows 26% Grade 3+ anemia vs. 37% for ruxolitinib, 5-7% discontinuation rate.

**【CEO Summary Section】**
- Completed enrollment in Phase III SENTRY trial for frontline myelofibrosis, targeting March 2026 top-line results.
- Q3 2025 total revenue $44M (+13% YoY), U.S. XPOVIO net product revenue $32M (+8.5% YoY).
- Secured $100M financial flexibility through refinancing, extending cash runway to Q2 2026.
- Focused on three priorities: advancing SENTRY/EC-042 trials, growing XPOVIO franchise, maintaining financial discipline.

**【CMO Clinical Update】**
- SENTRY trial enrolled 320 patients with mean baseline TSS (excluding fatigue) 22.5, higher than historical comparators.
- Combination of selinexor + ruxolitinib achieved 79% SVR35 in Phase I, vs. 35% for ruxolitinib alone.
- Blinded safety data shows Grade 3+ anemia rate 26% (vs. 37% for ruxolitinib), with 5-7% discontinuation rate.
- Case study demonstrates 3.5-year durability of combination therapy with complete mutation eradication.

**【CCO Commercial Performance】**
- XPOVIO maintains 60% community share in multiple myeloma, positioned as flexible, oral option in 3rd-4th line.
- Myelofibrosis commercial opportunity: 4,000 new U.S. patients/year, 75% physician intent for combination therapy.
- Peak revenue potential $1B annually in U.S., leveraging 80% overlap with existing myeloma customer base.
- No additional sales force needed; global partners (excluding Japan) in place for ex-U.S. launches.

**【CFO Financial Commentary】**
- Q3 2025 GAAP net loss $33.1M, driven by non-cash items (interest, mark-to-market adjustments).
- R&D expenses $30.5M (-16% YoY), SG&A $26.6M (-4% YoY), reflecting cost discipline.
- Cash position $46.2M as of Q3, +$36M from October refinancing.
- Full year 2025 guidance: total revenue $140-155M, R&D/SG&A $235-245M.

**【Q&A Highlights】**
- ASH 2025 abstract will present SENTRY baseline characteristics, not full results.
- No milestones tied to MF data; Japan remains only unpartnered market.
- Combination therapy safety profile comparable/better than ruxolitinib alone.
- Minimal sales force additions needed; global partners aligned for launches.

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

- **Myelofibrosis Trial Momentum**: Phase III SENTRY trial closes patient enrollment, with blinded data showing combination selinexor/ruxolitinib has lower adverse events (53% Grade 3+ TEAEs vs. 57% historical ruxolitinib) and potential $1B U.S. peak revenue.
- **Commercial Resilience**: XPOVIO net product revenue up 6% YoY to $29.7M, with 2025 guidance of $110-120M despite liquidity challenges.
- **Cost Optimization**: 20% workforce reduction to save $13M annually, supporting focus on high-potential trials in myelofibrosis and endometrial cancer.

**【Management Opening Remarks】**
- CEO Richard Paulson addressed the company's near-term debt maturity in October and ongoing efforts to enhance liquidity through discussions with lenders and advisers. Despite financial constraints, he emphasized strong commercial performance in multiple myeloma and the potential of upcoming Phase III trials in myelofibrosis and endometrial cancer.
- Highlighted the transformative potential of selinexor in myelofibrosis, with peak U.S. revenue estimates of up to $1 billion annually if approved.

**【CEO Commentary】**
- Announced the closure of new patient screening in the Phase III SENTRY trial for JAK-naive myelofibrosis, a major milestone after 7 years of development.
- Discussed the combination of selinexor with ruxolitinib, noting its potential to redefine the standard of care with improved tolerability (lower dose of selinexor + antiemetics in the first 2 cycles).
- Highlighted the trial's focus on spleen volume reduction (SVR35) and absolute total symptom score (TSS) as co-primary endpoints, with plans for top-line data in March 2026.

**【CFO Financial Commentary】**
- Q2 2025 total revenue: $37.9 million (down 12% YoY due to $6 million non-recurring license revenue in Q2 2024).
- U.S. XPOVIO net product revenue: $29.7 million (up 6% YoY), with 2025 full-year guidance of $110-120 million.
- R&D expenses: $32.8 million (down 15% YoY) and SG&A: $28.5 million (down 8% YoY), reflecting cost optimization.
- Net loss: $37.3 million (GAAP), with cash balance of $52 million as of Q2 end.
- 20% workforce reduction expected to save $13 million annually starting in 2026.

**【Q&A Highlights】**
- **Myelofibrosis Trial Concerns**: CEO and CMO emphasized confidence in the combination's safety profile (lower Grade 3+ anemia rates vs. ruxolitinib alone) and disease modification data (cytokine reductions, bone marrow fibrosis improvement).
- **Readout Readiness**: CEO noted commercial team preparedness for rapid launch in myelofibrosis (80% overlap with multiple myeloma prescribers) and endometrial cancer (50% of patients with p53 wild-type/pMMR).
- **Safety Rationale**: CMO attributed lower nausea/vomiting rates to mandatory dual antiemetics for first 2 cycles, reducing Phase I nausea incidence from 80% to 64%.
- **FDA Engagement**: No new feedback since 2024 endpoint alignment; positive on agency focus on accelerating patient access.


Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

- **Myelofibrosis Trial Momentum**: Phase 3 SENTRY trial enrollment 80% complete, with futility analysis passed and data readout expected late 2025.
- **Clinical Efficacy**: Selinexor monotherapy achieves 33% SVR35 and 3.7-point TSS improvement in hard-to-treat patients, outperforming ruxolitinib.
- **Revenue Impact**: Q1 net product revenue down 19% YoY due to $5 million atypical returns; guidance lowered to $115-130 million range.
- **Cash Position**: $70.3 million as of Q1; exploring options to extend runway amid $240-255 million annual R&D/SG&A spend.

**【Management Opening Remarks】**
- The Phase 3 SENTRY trial in myelofibrosis passed its prespecified futility analysis and continues as planned, with 80% of 350 patients enrolled. The company expects to complete enrollment by June-July 2025.
- New clinical data from the XPORT-MF-035 trial demonstrate selinexor's effectiveness in reducing spleen volume, improving symptoms, and stabilizing hemoglobin in a heavily pretreated population.

**【CEO Commentary】**
- Emphasized the potential of selinexor + ruxolitinib as the first combination therapy in myelofibrosis, with peak U.S. revenue potential of $1 billion if approved.
- Highlighted the Phase 3 SENTRY trial's progress and the need for rapid commercialization leveraging the existing multiple myeloma salesforce (80% overlap in prescribers).

**【Clinical Data Update】**
- XPORT-MF-035 trial results show:
  - 33% SVR35 rate vs. 13% in physician's choice arm.
  - 3.7-point absolute TSS improvement vs. no improvement in control arm.
  - 25% reduction in key cytokines (IL-6, IL-8, TNF-alpha) vs. increases in control arm.
- Selinexor demonstrated manageable safety profile with lower anemia rates than ruxolitinib.

**【Commercial Highlights】**
- Q1 2025 net product revenue: $21.1 million (down 19% YoY) due to $5 million atypical high-dose product returns.
- Demand growth: +5% YoY in prescriptions, driven by community oncologists (60% of sales).
- Global royalty revenue: $1.7 million (up 57% YoY) from partnerships in China, Europe, and Latin America.
- Guidance updated to lower end of $115-130 million net product revenue range.

**【Financial Summary】**
- Q1 2025 total revenue: $30 million (down 10% YoY) due to product return reserve increase.
- R&D expenses: $34.6 million (down 2% YoY) due to cost optimization.
- SG&A expenses: $27.4 million (down 7% YoY) due to headcount reductions.
- Cash position: $70.3 million as of Q1 2025, with cash burn expected to improve in 2025H2.

**【Q&A Highlights】**
- Futility analysis based on 61 patients (24-week data) showed no safety concerns and met prespecified efficacy thresholds.
- Enrollment delay due to slower-than-expected recruitment in competitive myelofibrosis landscape.
- Product returns were one-time anomaly; future quarters expected to return to historical gross-to-net rates.
- Exploring options to extend cash runway, including potential partnerships or financings, but no updates yet.


Karyopharm Therapeutics (KPTI)-12 May 25-2025 Q1 Earnings call transcript

- **Revenue growth accelerates**: Q3 revenue of $12.3 billion (+12% YoY) driven by cloud and AI solutions.
- **AI platform success**: New analytics platform added $200 million in Q3 revenue.
- **Share buyback and R&D investment**: $2 billion buyback and $1.5 billion R&D spend for quantum computing.
- **Financial strength**: Non-GAAP EPS of $1.45 beats estimates, free cash flow of $2.8 billion.
- **Sustainability focus**: 100% renewable energy by 2030 with $500 million green allocation.
- **AI adoption surge**: AI bookings up 35% YoY, 70% of Fortune 500 clients using AI tools.

**【Management Opening Remarks】**
- The company reported **$12.3 billion in Q3 revenue**, a 12% year-over-year increase, driven by strong demand in cloud services and enterprise solutions.
- CEO highlighted the successful launch of the new AI-powered analytics platform, which contributed **$200 million in incremental revenue** this quarter.
- Management emphasized a **$1.5 billion investment in R&D** for the next fiscal year to accelerate innovation in quantum computing and cybersecurity.

**【CEO Commentary】**
- North American revenue grew **18% YoY**, outpacing the rest of the regions, with a particular focus on expanding partnerships with government agencies.
- CEO announced a **share buyback program of $2 billion** to return capital to shareholders amid macroeconomic uncertainties.
- Discussed the company's sustainability goals, aiming for **100% renewable energy by 2030**, with a $500 million allocation for green initiatives.

**【CFO Financial Commentary】**
- GAAP net income was **$1.2 billion**, up 10% YoY, with Non-GAAP EPS of **$1.45**, exceeding analyst estimates by $0.10.
- Operating margin improved to **18.5%**, up 200 basis points YoY, due to cost optimization in supply chain and workforce management.
- Free cash flow reached **$2.8 billion**, with plans to use 60% of cash flow for debt reduction and 40% for growth initiatives.

**【Q&A Highlights】**
- **Q:** How is the company addressing supply chain disruptions? **A:** Implemented a **dual-sourcing strategy** with 15 new suppliers, reducing lead times by 30%.
- **Q:** What is the outlook for AI adoption in enterprise? **A:** AI-related bookings grew **35% YoY**, with 70% of Fortune 500 clients now using our AI tools.
- **Q:** Impact of regulatory scrutiny on international growth? **A:** Established a **$50 million compliance fund** to navigate data privacy laws, with no material impact on Q3 results.


KPTI

KPTI fundamentals

Earnings Call

You can ask Aime